The Bracco Group announces the newly-created Bracco Japan The Bracco Group announces its direct presence in the Japanese market, where it has been doing business since 1990 through a successful joint venture with Eisai

Bracco Diagnostics Inc. Branded Max 3™ received FDA 510(k) clearance Bracco Diagnostics Inc. Branded Max 3TM, a Rapid Exchange and Syringeless Injector, received FDA 510(k) clearance adding evolving innovation in Magnetic Resonance Imaging (MRI) and its product portfolio.

CitraClear signup form

Bracco Suisse and Verasonics: a new strategic partnership The collaboration focuses on combining Verasonics' Vantage®️ NXT Research Ultrasound Systems with Bracco's contrast agents to explore improved imaging performance in various research applications.

Bracco Diagnostics Inc. Announces Update on Product Portfolio Strategic decisions enable Bracco to serve better the needs of healthcare providers and patients with its enhanced pipeline offering.

Blue Earth Diagnostics appoints Marco Campione as Chief Executive Officer Mr. Campione brings more than 25 years global experience in successful development and commercialization of diagnostic imaging agents and radiopharmaceuticals.

Bracco Imaging awarded EcoVadis Gold Medal for the second time Bracco Imaging has been reconfirmed amongst the top 5% of 100,000 global companies certified by EcoVadis for the second year in a row

Join Bracco at RSNA 2024 Explore the Bracco Booth #3300 as Bracco Diagnostics Inc. showcases its innovations and more at the 2024 Radiological Society of North America Annual Congress.

Bracco Diagnostics Inc. Introduces CitraClear™ to the Healthcare Community Bracco Diagnostics Inc. (BDI) proudly unveils CitraClearTM, a pre-procedure hydration beverage designed with patients in mind. 

Bracco Imaging and Arrayus Technologies: a new strategic partnership Bracco Imaging and Arrayus Technologies have partnered to improve drug delivery for pancreatic cancer using focused ultrasound and microbubble technology.